← Back to Search

Behavioral Intervention

Psychosocial therapy for cannabis use disorder. for Cannabis Use Disorder

N/A
Waitlist Available
Led By Brian J Sherman, Ph.D.
Research Sponsored by Medical University of South Carolina
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Meet DSM-5 criteria for current moderate to severe CUD (past 60 days).
Identify cannabis as their primary substance of choice.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 8 weeks
Awards & highlights

Study Summary

This trial is investigating a new treatment for cannabis use disorder that targets implicit reward-driven processes. The study is a four-session randomized, double-blind, sham-controlled pilot treatment trial. One-hundred and six (106) treatment-seeking adults with moderate to severe CUD will be recruited, with an equal number of men and women. The study will test whether the treatment reduces cannabis cue-reactivity and cannabis use.

Eligible Conditions
  • Cannabis Use Disorder

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You primarily use cannabis as your drug of choice.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~8 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 8 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in cannabis cue-reactivity
Secondary outcome measures
Change in creatinine-adjusted cannabinoid levels
Change in percent days abstinent

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Active ABM + CBT/METExperimental Treatment2 Interventions
Participants in the Active ABM condition will receive approach bias modification (ABM) training sessions aimed at reducing cognitive bias for cannabis cues. All participants will receive MET/CBT therapy.
Group II: Sham ABM + CBT/METPlacebo Group2 Interventions
Participants in the Sham ABM condition will undergo similar computerized tasks without the manipulation of response contingencies that target modification of approach bias. All participants will receive MET/CBT therapy.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Psychosocial therapy for cannabis use disorder.
2019
N/A
~110
Approach Bias Modification (ABM)
2019
N/A
~110

Find a Location

Who is running the clinical trial?

Medical University of South CarolinaLead Sponsor
929 Previous Clinical Trials
7,393,715 Total Patients Enrolled
National Institute on Drug Abuse (NIDA)NIH
2,447 Previous Clinical Trials
2,593,964 Total Patients Enrolled
Brian J Sherman, Ph.D.Principal InvestigatorMedical University of South Carolina

Media Library

Approach Bias Modification (ABM) (Behavioral Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT03629990 — N/A
Cannabis Use Disorder Research Study Groups: Active ABM + CBT/MET, Sham ABM + CBT/MET
Cannabis Use Disorder Clinical Trial 2023: Approach Bias Modification (ABM) Highlights & Side Effects. Trial Name: NCT03629990 — N/A
Approach Bias Modification (ABM) (Behavioral Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03629990 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the trial accepting new participants at this time?

"The clinicaltrials.gov database indicates that this trial is actively enrolling patients, with the initial posting made on November 5th 2018 and subsequent edits taking place as recently as November 28th 2022."

Answered by AI

To what extent is this clinical experiment being participated in?

"Correct. The clinicaltrials.gov website reveals that this medical study, which was first posted on November 5th 2018, is actively recruiting patients. Approximately 106 individuals must be recruited from a single site."

Answered by AI

Does the criteria for this clinical trial allow individuals below 65 years of age to participate?

"To be considered for this trial, the patient must fall in the 18-65 age range. For those under or over that threshold, there are 15 and 48 alternative clinical trials respectively."

Answered by AI

Who is considered to be the ideal candidate for this clinical experiment?

"This clinical trial seeks 106 participants with a history of hashish abuse, between the ages 18 and 65. Crucially, volunteers must agree to remain abstinent from alcohol for 12 hours prior to study visits and other drugs (except nicotine) for 72 hours before their participation in this research. This is necessary so that all data collected may be free from any influence caused by recent substance use."

Answered by AI
~17 spots leftby Mar 2025